What can we help you find?

Leading the way in transplantation

Filter results for:

Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive characterisation of allograft rejection.

The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression optimisation.

However, there is no standard recognition of the usage of this new technology. As such, ESOT will drive and coordinate a whitepaper about molecular biomarkers for the non-invasive diagnosis of rejection that is aimed at providing a full European landscape and address unmet clinical needs.

Topic Chairs: John Friedewald (Kidney) Marina Berenguer (Liver) & Luciano Potena (Heart)

Steering Committee for Kidney: Dany Anglicheau, Oriol Bestard, John Friedewald, Claire Tinel, Sook Park, Joana Sellares

Steering Committee for Heart: Maria Crespo Leiro, Kiran Khush, Ingvild Birschmann, Javier Segovia, Andriana Nikolova, Annamaria Minervini

Steering Committee for Liver: Amelia Heissheimer, Eleonora de Martin, Valeria Mas, Josh Levitsky, Haseeb Zubair, Alina Lutu, Nabeel Wahid

Steering Committee for Lung: Sean Agbor-Enoh, Robin Vos

 

Heart and Lung

           

Kidney

           

Liver

           

Join our community today!

Learn more
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.